Virtu Financial’s BioXcel Therapeutics BTAI Stock Holding History

Virtu Financial’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23K	Buy	+15,967	New	+$18.7K	﹤0.01%	1329
2025 Q2	–	Sell	-10,666	Closed	-$22K	–	1495
2025 Q1	$22K	Buy	10,666 +9,605	+905%	+$35.9K	﹤0.01%	1092
2024 Q4	$6K	Buy	+1,061	New	+$8.86K	﹤0.01%	1421
2024 Q3	–	Sell	-3,584	Closed	-$73K	–	1407
2024 Q2	$73K	Buy	3,584 +2,710	+310%	+$90.7K	0.01%	862
2024 Q1	$39K	Sell	874 -2,846	-77%	-$136K	﹤0.01%	1059
2023 Q4	$176K	Buy	+3,720	New	+$207K	0.01%	880
2022 Q1	–	Sell	-768	Closed	-$250K	–	1528
2021 Q4	$250K	Buy	+768	New	+$330K	0.03%	728

Other funds holding BTAI

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtu Financial's BTAI Position: Q2 2026 in Review

Virtu Financial opened a new position in BioXcel Therapeutics (BTAI) in Q2 2026: 15,967 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #1329 among its holdings. This is a return to the name: Virtu Financial previously reported a position in BTAI as recently as Q1 2025.

Virtu Financial first reported a position in BTAI in Q4 2021 and has held it in 7 quarters since. The position peaked at $250K in Q4 2021. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

Virtu Financial held 15,967 shares of BioXcel Therapeutics worth $23K as of Q2 2026.
BioXcel Therapeutics was a new Virtu Financial position in Q2 2026.
BioXcel Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1329 holding.
Virtu Financial first reported a position in BioXcel Therapeutics in Q4 2021 and has held it in 7 quarters since.
Virtu Financial's BioXcel Therapeutics position peaked at $250K in Q4 2021.
47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.